PD-1 and PD-L1 Antibodies in Lung Cancer

The first pretreated patient with HER2-altered non–small cell lung cancer was dosed with NVL-330, a novel HER2-selective inhibitor, in the HEROEX-1 trial.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

The tyrosine kinase inhibitor entrectinib shows promising responses in patients with non–small cell lung cancer harboring a ROS1 mutation.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Juneko Grilley-Olson, MD, discussed findings from a phase 2 study investigating the addition of immunotherapy to chemotherapy for the treatment of advanced angiosarcoma.

Robert Jotte, MD, PhD, discussed findings from the phase 3 KRYSTAL-12 study evaluating adagrasib vs docetaxel in previously treated KRAS G12C-mutated non–small cell lung cancer.